July 23rd 2025
Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited options.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Age Is Not a Risk Factor for Post-Mastectomy Reconstructive Surgery
Employers Express Their Concerns With Cancer Care at the COA Summit
How Can Practices Seek Success With Oncology Payment Reform?
Dr Marianne Fazen on Why Cancer Is a Major Concern for Employers